Drug news
NICE recommends Xalkori (crizotinib) as second line therapy for NSCLC patients.- Pfizer
The National Institute for Health and Care Excellence (NICE) has recommended Xalkori (crizotinib) from Pfizer as second line therapy for NSCLC patients. An earlier NICE Recommendation for the drug was for first line therapy for ALK positive advanced NSCLC. New clinical evidence and a discount provided the basis for the new recommendation.
Comment:Crizotinib is the first pill-based alternative to intravenous chemotherapy used to treat advanced non-small-cell lung cancer.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.